Microtubule-associated protein 2 phosphorylation is decreased in the human epileptic temporal lobe cortex.
Microtubule-associated protein 2 (MAP2) is an abundant component of the neuronal cytoskeleton whose function is related to the outgrowth and stability of neuronal processes, to synaptic plasticity and neuronal cell death. We have sought to study whether abnormal patterns of neuronal activity which are characteristic of epileptic patients are associated to alterations of MAP2 phosphorylation. An antibody (305) that selectively recognizes a phosphorylated epitope in a proline-rich region of the MAP2 molecule has been used to analyze neocortical biopsy samples from temporal lobe epileptic patients, whose electrocorticogram activity had been previously monitored. Immunoblot analysis showed that samples with greater spiking activity displayed significantly diminished MAP2 phosphorylation. Immunocytochemical analysis revealed the occurrence of discrete areas in the neocortex with highly decreased or no immunostaining for antibody 305, which showed a clear, although non-significant, tendency to appear more frequently in areas with greater spiking activity. To further support an association between epileptiform activity and MAP2 dephosphorylation an experimental model of epileptiform activity in cultures of rat hippocampal neurons was used. Neurons were cultured during 15 days in the presence of kynurenic acid, an antagonist of glutamate receptors. At this time, kynurenic acid was removed from the culture medium and neurons developed seizure-like activity. Using antibody 305, we found a decrease of MAP2 phosphorylation that was already visible after 15 min of kynurenic acid withdrawal. We therefore propose that MAP2 phosphorylation is decreased in the neocortex of epileptic patients and that this decrease is a likely consequence of seizure activity. Also, MAP2 dephosphorylation may lead to alterations of the neuronal cytoskeleton and eventually to neuronal damage and loss, which is typical of epileptic patients.
Sánchez
C
C
Centro de Biología Molecular Severo Ochoa, Departamento de Biología Molecular, Facultad de Ciencias, Universidad Autónoma de Madrid, Spain.
Arellano
J I
JI
Rodríguez-Sánchez
P
P
Avila
J
J
DeFelipe
J
J
Díez-Guerra
F J
FJ
D000200:Action Potentials / Q000502:physiology; D000328:Adult; D000818:Animals; D002478:Cells, Cultured; D003599:Cytoskeleton / Q000378:metabolism* / Q000473:pathology; D015536:Down-Regulation / Q000502:physiology*; D004833:Epilepsy, Temporal Lobe / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005333:Fetus; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009410:Nerve Degeneration / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D009474:Neurons / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation; D051381:Rats; D013702:Temporal Lobe / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology
D008869:Microtubule-Associated Proteins